Entering text into the input field will update the search result below

Omeros: The Weight Of The Wait, A Conundrum

May 02, 2022 10:18 PM ETOmeros Corporation (OMER)73 Comments
Out of Ignorance profile picture
Out of Ignorance


  • Omeros' OMIDRIA sale has substantially improved its financial prospects.
  • Omeros' CRL gangplank is agonizing for shareholders as they wait for FDA response to its type A meeting.
  • Omeros' growing short interest and its sinking share price will likely continue until it provides positive feedback on its FDA interactions.

Sad unhappy teenage girl

bymuratdeniz/E+ via Getty Images

Omeros (NASDAQ:OMER) is a long term favorite that has fallen on hard times. In this article I update the status of its OMIDRIA (phenylephrine and ketorolac intraocular solution) sale and of its CRL for narsoplimab (OMS721; MASP-2 Inhibitor, Lectin Pathway).

Omeros 2022 10-K

Omeros 2022 10-K (seekingalpha.com)

Data by YCharts

This article was written by

Out of Ignorance profile picture
Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of OMER either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I may buy or sell interests in any company mentioned over the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.